Literature DB >> 23264191

Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy.

Paolo Farace1, Dante Amelio, Giuseppe K Ricciardi, Giada Zoccatelli, Stefano Magon, Francesca Pizzini, Franco Alessandrini, Andrea Sbarbati, Maurizio Amichetti, Alberto Beltramello.   

Abstract

To investigate the increase in MRI contrast enhancement (CE) occurring in glioblastoma during the period between surgery and initiation of chemo-radiotherapy, thirty-seven patients with newly diagnosed glioblastoma were analyzed by early post-operative magnetic resonance (EPMR) imaging within three days of surgery and by pre-adjuvant magnetic resonance (PAMR) examination before adjuvant therapy. Areas of new CE were investigated by use of EPMR diffusion-weighted imaging and PAMR perfusion imaging (by arterial spin-labeling). PAMR was acquired, on average, 29.9 days later than EPMR (range 20-37 days). During this period an increased area of CE was observed for 17/37 patients. For 3/17 patients these regions were confined to areas of reduced EPMR diffusion, suggesting postsurgical infarct. For the other 14/17 patients, these areas suggested progression. For 11/17 patients the co-occurrence of hyperperfusion in PAMR perfusion suggested progression. PAMR perfusion and EPMR diffusion did not give consistent results for 3/17 patients for whom small new areas of CE were observed, presumably because of the poor spatial resolution of perfusion imaging. Before initiation of adjuvant therapy, areas of new CE of resected glioblastomas are frequently observed. Most of these suggest tumor progression, according to EPMR diffusion and PAMR perfusion criteria.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23264191     DOI: 10.1007/s11060-012-0997-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

Review 1.  Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?

Authors:  Yaacov Richard Lawrence; Deborah T Blumenthal; Diana Matceyevsky; Andrew A Kanner; Felix Bokstein; Benjamin W Corn
Journal:  J Neurooncol       Date:  2011-04-24       Impact factor: 4.130

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

3.  Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI.

Authors:  P Farace; M G Giri; G Meliadò; D Amelio; L Widesott; G K Ricciardi; S Dall'Oglio; A Rizzotti; A Sbarbati; A Beltramello; S Maluta; M Amichetti
Journal:  Br J Radiol       Date:  2010-11-02       Impact factor: 3.039

4.  Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.

Authors:  Christina Tsien; Craig J Galbán; Thomas L Chenevert; Timothy D Johnson; Daniel A Hamstra; Pia C Sundgren; Larry Junck; Charles R Meyer; Alnawaz Rehemtulla; Theodore Lawrence; Brian D Ross
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

5.  Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.

Authors:  Seymur Gahramanov; Ahmed M Raslan; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Csanad G Varallyay; Jeffrey M Njus; Marianne Haluska; Edward A Neuwelt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-13       Impact factor: 7.038

6.  Clinical and radiographic features of peritumoral infarction following resection of glioblastoma.

Authors:  S Ulmer; T A Braga; F G Barker; M H Lev; R G Gonzalez; J W Henson
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

7.  Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury.

Authors:  Justin S Smith; Soonmee Cha; Mary Catherine Mayo; Michael W McDermott; Andrew T Parsa; Susan M Chang; William P Dillon; Mitchel S Berger
Journal:  J Neurosurg       Date:  2005-09       Impact factor: 5.115

8.  Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor regrowth and recurrence.

Authors:  Gazanfer Ekinci; Ihsan N Akpinar; Feyyaz Baltacioğlu; Canan Erzen; Türker Kiliç; Ilhan Elmaci; Necmettin Pamir
Journal:  Eur J Radiol       Date:  2003-02       Impact factor: 3.528

9.  End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Authors:  Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen; David R Macdonald; Susan M Chang
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

10.  A pilot study of brain tumour growth between radiotherapy planning and delivery.

Authors:  C Pennington; L Kilbride; R Grant; J M Wardlaw
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-03       Impact factor: 4.126

View more
  16 in total

1.  MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.

Authors:  K Yamashita; A Hiwatashi; O Togao; K Kikuchi; R Hatae; K Yoshimoto; M Mizoguchi; S O Suzuki; T Yoshiura; H Honda
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-24       Impact factor: 3.825

2.  Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes.

Authors:  Javier E Villanueva-Meyer; Seunggu J Han; Soonmee Cha; Nicholas A Butowski
Journal:  J Neurooncol       Date:  2017-05-31       Impact factor: 4.130

Review 3.  Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.

Authors:  Fabrício Guimarães Gonçalves; Sanjeev Chawla; Suyash Mohan
Journal:  J Magn Reson Imaging       Date:  2020-03-19       Impact factor: 4.813

4.  Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.

Authors:  Yu Jin Lim; Il Han Kim; Tae Jin Han; Seung Hong Choi; Sung-Hye Park; Chul-Kee Park; Sun Ha Paek; Se-Hoon Lee; Tae Min Kim
Journal:  Int J Clin Oncol       Date:  2014-04-05       Impact factor: 3.402

5.  Prediction value of unmeasurable MR enhancement at early stage after gross-total resection on the survival state of patients with high-grade glioma.

Authors:  Guanmin Quan; Yongli Zheng; Jun Chen; Bei Hua; Xiaoli Ji; Kexin Zhang; Duo Gao; Jianming Lei; Tao Yuan
Journal:  J Neurooncol       Date:  2018-09-04       Impact factor: 4.130

6.  Interval brain imaging for adults with cerebral glioma.

Authors:  Gerard Thompson; Theresa A Lawrie; Ashleigh Kernohan; Michael D Jenkinson
Journal:  Cochrane Database Syst Rev       Date:  2019-12-24

7.  Post-treatment imaging of high-grade gliomas.

Authors:  Darshana Sanghvi
Journal:  Indian J Radiol Imaging       Date:  2015 Apr-Jun

8.  Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.

Authors:  Paulo Linhares; Bruno Carvalho; Rita Figueiredo; Rui M Reis; Rui Vaz
Journal:  J Oncol       Date:  2013-08-13       Impact factor: 4.375

9.  Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.

Authors:  Sonia Tejada; Guillermo Aldave; Miguel Marigil; Jaime Gállego Pérez-Larraya; Jaime de Gallego; Pablo Daniel Domínguez; Ricardo Díez-Valle
Journal:  J Neurooncol       Date:  2013-10-18       Impact factor: 4.130

10.  Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.

Authors:  Eun Kyoung Lee; Seung Hong Choi; Tae Jin Yun; Koung Mi Kang; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Sung-Hye Park; Il Han Kim
Journal:  Korean J Radiol       Date:  2015-10-26       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.